Miruvor
Sign up
The short answer

What studies of Brain training games (Lumosity) found

9papers on Brain training games (Lumosity)
62people in 1 study testing Brain training games (Lumosity) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the randomised trial and studies with no comparison group (very low certainty): 5 of 6 findings are D.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Brain training games (Lumosity) for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 9 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Brain training games (Lumosity) · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Fatigue1 study · 62 people took part in Brain training games (Lumosity) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

Fatigue improved.

The evidence is very uncertain about the effect of brain training games (Lumosity) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    PROMIS fatigue T scoreb Patient-Reported Outcomes Measurement Information System
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety1 study · 62 people took part in Brain training games (Lumosity) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the change wasn't shown to be more than chance.

Studies with no comparison group328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

No clear change in anxiety.

The evidence is very uncertain about the effect of brain training games (Lumosity) on anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    PROMIS anxiety T scoreb Patient-Reported Outcomes Measurement Information System
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 62 people took part in Brain training games (Lumosity) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 328 people found no clear difference; a small benefit can't be ruled out; effect size 0.00 (very small).

The randomised trial328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of brain training games (Lumosity) on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 328 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Brain training games (Lumosity) with active comparator (video puzzles and games).

See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    BrainHQ vs active comparator modified Everyday Cognition Scale 2
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Depression1 study · 62 people took part in Brain training games (Lumosity) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the change wasn't shown to be more than chance.

Studies with no comparison group328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

No clear change in depression.

The evidence is very uncertain about the effect of brain training games (Lumosity) on depression in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    PROMIS depression T scoreb Patient-Reported Outcomes Measurement Information System
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 62 people took part in Brain training games (Lumosity) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the change wasn't shown to be more than chance.

Studies with no comparison group328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

No clear change in low mood or anxiety.

The evidence is very uncertain about the effect of brain training games (Lumosity) on low mood or anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    PROMIS distress (raw)b Patient-Reported Outcomes Measurement Information System
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 62 people took part in Brain training games (Lumosity) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the change wasn't shown to be more than chance.

Studies with no comparison group328 randomised · 320 started · at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention · 30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks

No clear change in sleep.

The evidence is very uncertain about the effect of brain training games (Lumosity) on sleep in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial. (2026)

    People in the study
    328 randomised · 320 started
    Dose
    30 minutes, 5 times per week, over the 10-week intervention, 5 times per week over 10 weeks
    Outcome
    PROMIS Sleep 8b T scoreb Patient-Reported Outcomes Measurement Information System
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

Stopping because of side effects1 study

All papers

  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.2026 · randomised trial · 328 randomised · 320 started
    Summary

    This 5-arm, multicenter randomized trial asked whether remotely delivered rehabilitation strategies improve cognitive symptoms in people with cognitive long COVID. It enrolled 328 participants at 22 trial sites in the US; 320 received at least 1 intervention. Over 10 weeks, participants were assigned to adaptive online BrainHQ, PASC-CoRE (9 90-minute group sessions and 3 30-minute individual sessions) plus BrainHQ, active tDCS (2.0 mA for 30 minutes) plus BrainHQ, an active comparator of online puzzles and games, or sham tDCS plus BrainHQ, with interventions 5 times per week. The primary outcome was the modified ECog2 at the end of intervention. There were no differences on the modified ECog2 for any prespecified primary treatment comparison in the ITT population (N = 328); adjusted differences were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (−0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. At EOI, the modified ECog2 improved in the range of approximately half an SD in all study arms; secondary outcomes showed no differential benefits. On the overall-functioning item, 4/300 (1.3%) reported much worse and 16/300 (5.3%) somewhat worse; 222/299 (74.2%) said the intervention helped cognitive functioning. At EOI, 143 participants (56%) reported postexertional malaise; no participants discontinued prematurely due to postexertional malaise. In the modified ITT population (n = 320), 11 participants experienced treatment-emergent serious adverse events; there were no serious adverse events attributable to the interventions, and one participant receiving active tDCS reported a minor thermal injury. Limitations included uncertainties about the pathobiology and possible unexpected therapeutic benefits from the active comparator.

  2. Cognitive remediation training improves performance in patients with chronic fatigue syndrome.2017 · compared with another group
    Summary

    This contemporaneous, case-control trial (not formally randomized) asked whether adding an online, home-based cognitive remediation training program (CET) to CBT/GET improves outcomes in chronic fatigue syndrome. Two groups of 36 patients were recruited from an academic, tertiary referral outpatient clinic in Sydney; allocation used consecutive time windows and was not concealed. Both groups received CBT/GET delivered in 11 sessions over 12 weeks. The CET arm also completed 3–5 exercises up to a total of 40 sessions. Outcomes included the SPHERE Composite Neurocognitive Symptoms score, SOMA and PSYCH scores, SF-36 Physical and Social Functioning, and, in the CET arm only, neuropsychological tests. Follow-up was at 24 weeks post-baseline. The Composite Neurocognitive Symptoms score improved in both groups; a group by time interaction was significant (F(2,63)=4.16, p=0.020), and post-hoc comparison showed a significant difference only at follow-up (t(66)=2.50, p=0.015), with fewer symptoms in the CET group. SOMA and SF-36 measures showed no significant group main effects; PSYCH showed no significant group main effect but a significant group by time interaction. Within the CET arm, Trail Making Test Part B, Digit Span Backwards, RAVLT proactive interference, and Visual Elevator Timing improved. No serious adverse effects of CET were reported; some patients reported feeling mentally fatigued after sessions. The CET arm had 33 at end treatment and 31 at follow-up; four completed no online exercises. Withdrawals due to harms were not reported.

  3. Computerized training improves verbal working memory in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A pilot study.2015 · compared with another group
    Summary

    This non-randomized pilot study asked whether computerized working memory training could reduce working memory deficits in patients with ME/CFS recruited from a 6-month outpatient rehabilitation programme, also described as lasting 17–20 weeks, at Danderyd University Hospital, Stockholm. Eleven patients with signs of working memory deficit were recruited for additional memory training and 12 patients with no working memory deficit served as controls. Training used Cogmed QM for approximately 30–45 min/day, 5 days/week over a 5-week period, added to the rehabilitation programme; controls received standard rehabilitation services. Digit Span forward, backward and total (Global Digit Span) were the primary measures, reassessed 2–3 weeks after training and 1–3 weeks after rehabilitation. Nine of the 11 patients completed training; 3 could not train at the pre-planned intensity and received prolonged periods of 6, 7 or 10 weeks; 2 of 11 did not complete and were excluded, 1 lost motivation and 1 reported elevated ME/CFS symptoms that returned to previous level after stopping. In the training group, BDS increased (p = 0.016), GDS increased (p = 0.0001), and FDS showed a trend (p = 0.052); the abstract reports working memory p = 0.003, general attention p = 0.004 and short-term memory p = 0.052, not significant. The control group showed no significant improvement, and no significant between-group differences were found at second testing. One of 11 patients was excluded because of increased symptoms during training.

  4. Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
    Summary

    This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.

  5. Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.2025 · systematic review
    Summary

    This systematic review asked whether non-invasive or minimally invasive brain stimulation reduces symptoms of post-COVID-19 condition. Four databases were searched through April 2nd, 2024; 19 studies were included, covering tDCS, TMS, tVNS and toACS. Across the included studies, Klirová et al. (33 patients) found no significant intergroup difference in post-COVID-19 symptoms. Santana et al. (70 patients) reported a significant reduction in fatigue and anxiety and an improvement in quality of life with active HD-tDCS compared with sham. Oliver-Mas et al. (47 patients) reported a significant improvement of physical fatigue and depressive symptoms in the active tDCS group compared with sham. Gracia et al. (15 patients) found no significant improvement across groups. Vestito et al. (7 patients) reported a significant improvement of hyposmia comparing tDCS with sham. Sakib et al. (4 patients) detected no significant group differences for rTMS. Badran et al. (13 patients) reported a trend towards mild to moderate effects of tVNS on fatigue. Reported harms included transient burning or tingling during tDCS, mild and transient headache and dizziness, transient tingling on the scalp, transient mild skin irritation with tVNS, and transient pain at the TMS stimulation site. The authors state that sample sizes are small, many studies are case reports, randomization and control groups are often missing, and diagnostic criteria differ.

  6. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.2024 · systematic review
    Summary

    This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.

  7. Digital Interventions Addressing Cognitive and Psychological Symptoms in Long COVID: Scoping Review of Multicomponent Approaches.2026 · review
    Summary

    This scoping review examined digital interventions for cognitive and psychological symptoms in people with long COVID. It included 25 (2.82%) records identified through a database search between December 2024 and February 2025. The records covered telehealth or telerehabilitation, virtual reality, mobile health apps, online psychological therapies, game-based cognitive training, neuromodulation (transcranial direct current stimulation), and multicomponent programs. No comparison was required for inclusion; comparators were reported when present. Outcomes concerned attention, memory, executive function, depression, anxiety, fatigue, and well-being. Reported effects were mixed. Telehealth or telerehabilitation records were summarized as improvements in quality of life, mental health (anxiety and depression), and self-efficacy, with mixed effects on cognition. Virtual reality records were summarized as enhanced emotional well-being and physical functioning, inconsistent effects on cognition, and some usability issues; some users reported side effects such as dizziness and headaches. Mobile health app records were summarized as gains in attention, mood, and self-reported recovery. Online psychological therapy records were summarized as decreased anxiety, posttraumatic stress disorder, and depression and high feasibility and acceptability. Game-based cognitive training was summarized as improved processing speed and task-switching and no sustained improvement in attention. Neuromodulation was summarized as enhanced cognition, mood, and energy levels in a small-scale pilot study. Multicomponent programs were summarized as broad improvements across mental health, cognitive symptoms, and physical activity. The authors state limitations including small sample sizes, lack of control groups, heterogeneity in outcomes and intervention protocols, and short follow-up durations, plus underrepresentation of older adults and underserved populations.

  8. A Narrative Review of the Efficacy of Long COVID Interventions on Brain Fog, Processing Speed, and Other Related Cognitive Outcomes.2025 · review
    Summary

    This narrative review asked which interventions have been studied for long COVID-associated neurocognitive deficits. It searched PubMed, Embase, and Scopus and included Twelve studies. Reports covered cognitive training, rTMS, exercise rehabilitation, antihistamines (fexofenadine and famotidine), Brainmax, PEA-LUT, aromatherapy, and CICT. For rTMS, one case study (n = 1) reported improved processing speed and perceptual reasoning scores; a case series (n = 4) reported that 3 of 4 participants improved on behavioral inhibition; a pilot case series (n = 23) reported a statistically significant increase in attention/concentration, memory, and planning/organizational abilities; and a case series (n = 12) reported a statistically significant increase in all four cognitive areas and FSIQ from 94.6 ± 10.9 to 104.4 ± 13.0. The REGAIN trial (585 adults; n = 298 intervention, n = 287 usual care) reported statistically significant improvement in health-related quality of life at 3 months and 12 months and in depression, fatigue, and sleep disturbance, but not in cognitive function at 12 months. Salvucci and colleagues (14 experimental, 13 control) reported that 43% of the experimental group reported vanishing of fatigue and 43% reported vanishing of brain fog; the control group reported no statistically significant improvements across symptoms. Brainmax versus placebo (15 and 15) showed a statistically significant reduction in MFI-20 scores and a slight increase in MoCA scores. CICT (n = 14; 80% of unemployed before CICT returned to work) reported improvements. Authors state limitations include absence of control group, low sample sizes, and no reported effect size calculations. Worsening, stopping, and side effects were not reported.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime